Hepato-gastroenterology最新文献_第9页

Endoscopic excavation for the treatment of small esophageal subepithelial tumors originating from the muscularis propria. 内镜下挖掘治疗源自固有肌层的食管上皮下小肿瘤。

Hepato-gastroenterology Pub Date : 2015-01-01

Li-ping Ye, Lin-hong Zhu, Xian-bin Zhou, Xin-li Mao, Yu Zhang

{"title":"Endoscopic excavation for the treatment of small esophageal subepithelial tumors originating from the muscularis propria.","authors":"Li-ping Ye, Lin-hong Zhu, Xian-bin Zhou, Xin-li Mao, Yu Zhang","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: This study was designed to evaluate the safety and efficacy of endoscopic excavation for esophageal subepithelial tumors originating from the muscularis propria.Methodology: Forty-five patients with esophageal subepithelial tumors originating from the muscularis propria were treated with endoscopic excavation between January 2010 and June 2012. The key steps were: (1) making several dots around the tumor; (2) incising the mucosa along with the marker dots, and then seperating the tumor from the muscularis propria by using a hook knife or an insulated-tip knife; (3) closing the artificial ulcer with clips after the tumor was removed.Results: The mean tumor diameter was 1.1 ± 0.6 cm. Endoscopic excavation was successfully performed in 43 out of 45 cases (95.6%), the other 2 cases were ligated with nylon rope. During the procedure perforation occurred in 4 (8.9%) patients, who recovered after conservative treatment. No massive bleeding or delayed bleeding occurred. Histologic diagnosis was obtained from 43 (95.6%) patients. Pathological diagnoses of these tumors were leiomyomas (38/43) and gastrointestinal stromal tumors (5/43).Conclusions: Endoscopic excavation is a safe and effective method for the treatment of small esophageal subepithelial tumors originating from the muscularis propria.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"65-8"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33251969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High intensity focused ultrasound ablation for patients with inoperable liver cancer. 高强度聚焦超声消融术治疗不能手术的肝癌。

Hepato-gastroenterology Pub Date : 2015-01-01

Lianyu Chen, Kun Wang, Zhen Chen, Zhiqiang Meng, Hao Chen, Huifeng Gao, Peng Wang, Huili Zhu, Junhua Lin, Luming Liu

{"title":"High intensity focused ultrasound ablation for patients with inoperable liver cancer.","authors":"Lianyu Chen, Kun Wang, Zhen Chen, Zhiqiang Meng, Hao Chen, Huifeng Gao, Peng Wang, Huili Zhu, Junhua Lin, Luming Liu","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: To analyses the feasibility and efficacy of high intensity focused ultrasound (HIFU) treatment in patients with inoperable liver cancer.Methodology: 187 patients were treated with HIFU, of all these patients 116 cases were Primary Liver Cancer (PLC) and 71 cases were Metastatic Liver Cancer (MLC). According to some parameters, such as clinical symptoms, the basis of main organs functional tests, imaging examinations, and progression-free survival (PFS) time to assess the safety and efficacy of HIFU in the treatment of liver cancer.Results: 55 patients (29.4%) achieved CR and 73 patients (39.0%) achieved PR, 32 patients (17.1%) had responses of SD, and 27 patients (14.4%) were PD, respectively. Response rates were 90.5% (32 CR + 6 PR/42) in left lobe cancer and 64.1% (22 CR + 62 PR/131) in right lobe cancer. The median PFS for those CR case was 7 months, of PLC was 8 months, of MLC was 5 months.Conclusions: HIFU is effective and feasible in the treatment of liver cancer. It offer a significant noninvasive therapy for local treatment of liver cancer. For those right lobe liver cancers or with poor ultrasonic window, increasing treatment time or repeated treatment may improve the efficiency of HIFU ablation.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"140-3"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33130555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgery of upper GI gastrointestinal stromal tumors: our experience, prognostic analysis. 上消化道间质瘤的手术治疗:经验及预后分析。

Hepato-gastroenterology Pub Date : 2015-01-01 DOI: 10.5754/HGE12819

Wisit Kasetsermwiriya, E. Nagai, Kohei Nakata, Y. Nagayoshi, S. Shimizu, Masao Tanaka

{"title":"Surgery of upper GI gastrointestinal stromal tumors: our experience, prognostic analysis.","authors":"Wisit Kasetsermwiriya, E. Nagai, Kohei Nakata, Y. Nagayoshi, S. Shimizu, Masao Tanaka","doi":"10.5754/HGE12819","DOIUrl":"https://doi.org/10.5754/HGE12819","url":null,"abstract":"BACKGROUND/AIMS To review our treatment experience of gastrointestinal stromal tumors (GISTs) of the upper gastrointestinal tract and identify the prognostic factors that influence tumor recurrence. METHODOLOGY Data of 46 consecutive patients with upper GI GISTs who underwent surgery from 1988 to 2011 were reviewed. The overall and disease-free survival rates and influence of clinicopathologic variables on disease-free survival rate were evaluated. RESULTS The median age was 64 years (range, 20-86 years). R0 resections were performed in 43 (93.5%) patients. With a median follow-up time of 33 months (1-275 months), there were 5 (10.9%) recurrences and 2 mortalities in the high-risk group. The overall survival and recurrence-free survival rates at 5 years were 92.1% and 84.6%, respectively. Male gender, tumor size of >10 cm, high numbers of mitotic figures, R1 resection, high risk according to the Joensuu criteria, and a Ki-67 index of >10% were associated with a poor prognosis. CONCLUSIONS Surgical resection of low- and intermediate-risk GISTs has excellent results. High counts of mitotic figures, male gender, incomplete resection, large tumor size, and a high Ki-67 index are associated with a poor prognosis.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"477 1","pages":"87-92"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71080227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS. 聚乙二醇干扰素α -2a (40 KD)和/或高剂量利巴韦林诱导治疗难以治疗的基因型1型CHC患者:来自PROGRESS的药代动力学和病毒动力学(PK/VK)评估

Hepato-gastroenterology Pub Date : 2015-01-01

Peter N Morcos, Ruby Leong, James A Thommes, Jean DePamphilis, Joseph F Grippo, Barbara J Brennan

{"title":"Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS.","authors":"Peter N Morcos, Ruby Leong, James A Thommes, Jean DePamphilis, Joseph F Grippo, Barbara J Brennan","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: PROGRESS randomized chronic hepatitis C genotype 1 patients with a baseline viral load ≥400,000 IU/mL weighing ≥85 kg to regimens of 180 μg/week for 48 weeks or 360 μg/week for 12 weeks followed by 180 μg/week for 36 weeks peginterferon alfa-2a plus ribavirin. This analysis explored pharmacokinetics and early viral kinetics (VK) and evaluates differences between groups.Methodology: Blood samples for pharmacokinetic and VK analyses were collected from 51 patients enrolled in the PROGRESS study.Results: Mean peginterferon alfa-2a trough concentration at week 12 was 11.7±4.3 ng/mL for 180 μg and 23.4±11.3 ng/mL for 360 μg. Early VK profiles suggested a trend towards an enhanced viral decline in the 360 μg groups with a mean decrease in HCV RNA at 48 hours post first dose of 1.04 log10 (IU/mL) compared with 0.76 log10 (IU/mL) in the 180 μg groups. Mean beta slope increased with dose, ranging from 0.38±0.26 log10 IU/week at 180 μg to 0.52±0.32 log10 IU/week at 360 μg.Conclusions: Early viral de clines may be enhanced with the 360 μg dose. These data may suggest the utility of high-dose peginterfer on alfa-2a plus direct-acting antivirals (DAA) in select difficult-to-treat populations.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"11-8"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33249640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of using low-dose computed tomography to assess patency in gastrointestinal tracts with a patency capsule. 使用低剂量计算机断层扫描评估胃肠通畅胶囊的有效性。

Hepato-gastroenterology Pub Date : 2015-01-01

Tomohiro Shirasawa, Shinichi Hashimoto, Kensaku Shimizu, Ryo Kawasato, Takayuki Yokota, Hiroaki Shibata, Hideko Onoda, Teppei Yonezawa, Takeshi Okamoto, Jun Nishikawa, Naofumi Matsunaga, Isao Sakaida

{"title":"Effectiveness of using low-dose computed tomography to assess patency in gastrointestinal tracts with a patency capsule.","authors":"Tomohiro Shirasawa, Shinichi Hashimoto, Kensaku Shimizu, Ryo Kawasato, Takayuki Yokota, Hiroaki Shibata, Hideko Onoda, Teppei Yonezawa, Takeshi Okamoto, Jun Nishikawa, Naofumi Matsunaga, Isao Sakaida","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: A patency capsule (PC) is used to safely perform capsule endoscopy. When the PC is not excreted within the defined time frame, radiography often cannot localize the PC. Computed tomography (CT) localizes a PC more definitively than radiography. We evaluated the localization of PCs using low-dose (LD)-CT.Methodology: Forty-nine patients received a PC and 33 did not excrete the PC within the defined time frame and underwent radiography and LDCT with a 90% exposure reduction.Results: LDCT localized the PC in 31 patients (93.9%), whereas radiography localized it in 7 (21.2%), indicating a significantly higher detection rate with LDCT (P<0.0001). PC retention in the small intestine was confirmed by LDCT in 4 patients. Retention was not observed during capsule endoscopy in the patients with confirmed patency of the gastrointestinal tract. In 21 patients who underwent LDCT with the conventional photographing area, the effective radiographic exposure dose associated with LDCT was 1.43±1.08 mSv. Conversely, in the 12 patients who underwent LDCT with a reduced photographing area, the effective dose was reduced to 0.62±0.27 mSv (P<0.05).Conclusion: LDCT with a reduced exposure dose can definitively localize a PC. Therefore, this method may allow capsule endoscopy to be performed for more diseases.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"240-4"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33251250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mesh erosion causes small bowel obstruction: a rare complication of laparoscopic inguinal hernia repair: case description and review of literature. 腹腔镜腹股沟疝修补术中一种罕见的并发症——补片糜烂引起小肠梗阻:病例描述及文献复习。

Hepato-gastroenterology Pub Date : 2015-01-01

Tong-min Xue, Li-de Tao, Jie Zhang, Pei-Jian Zhang

引用次数: 0

Totally laparoscopic right colectomy: technique description. 全腹腔镜右结肠切除术:技术描述。

Hepato-gastroenterology Pub Date : 2015-01-01

Wenguang Liu, Jie Li, Ketao Jin, Qinghuan Liu

引用次数: 0

Long-term outcomes after extrahepatic excision of congenital choladocal cysts: 30 years of experience at a single center. 先天性胆总管囊肿肝外切除后的长期预后:单一中心30年的经验。

Hepato-gastroenterology Pub Date : 2015-01-01

Hideo Ohtsuka, Koji Fukase, Hiroshi Yoshida, Fuyuhiko Motoi, Hiroki Hayashi, Takanori Morikawa, Takaho Okada, Kei Nakagawa, Takeshi Naitoh, Yu Katayose, Michiaki Unno

{"title":"Long-term outcomes after extrahepatic excision of congenital choladocal cysts: 30 years of experience at a single center.","authors":"Hideo Ohtsuka, Koji Fukase, Hiroshi Yoshida, Fuyuhiko Motoi, Hiroki Hayashi, Takanori Morikawa, Takaho Okada, Kei Nakagawa, Takeshi Naitoh, Yu Katayose, Michiaki Unno","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: Congenital choladocal cysts are generally treated by resection of the dilated extrahepatic biliary duct followed by hepaticojejunostomy, but it is associated with postoperative complications, including postoperative cholangitis, intrahepatic calculi, pancreatitis, and carcinogenesis, in the remnant bile duct. We investigated the most common long-term complications and identified the factors implicated in their development.Methodology: We conducted a retrospective review and analysis of the long-term complications of 65 patients surgically treated for congenital choledochal cysts between 1978 and 2008 at one institute. The risk factors for intrahepatic calculi were identified based on the odds ratios of the implicated variables.Results: Cholangitis with high fever or abdominal pain was reported in 14 patients (21.5%), intrahepatic calculi in 12 (18.5%), pancreatitis in 3 (4.6%), and cholangiocarcinoma in 3 (4.6%). Diagnosis with type IVa choledochal cysts was the most significant risk factor, followed by age ≥30 years at the time of treatment, and the presence of preoperative intrahepatic calculi.Conclusions: While precise and thorough surgical treatment is necessary to prevent the long-term development of complications after surgical excision of congenital choledochal cysts, it must be accompanied by long-term postoperative follow-up, especially of elderly patients and those with type IVa cysts.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33124960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials. 干扰素-α联合拉米夫定与拉米夫定单药治疗慢性乙型肝炎感染中YMDD突变的出现:随机对照试验的荟萃分析

Hepato-gastroenterology Pub Date : 2015-01-01

Ya-li Zhang, Jie Zhang, Li-yan Cui

{"title":"Interferon-α combined with lamivudine versus lamivudine monotherapy for the emergence of YMDD mutations in chronic hepatitis B infection: a meta-analysis of randomized controlled trials.","authors":"Ya-li Zhang, Jie Zhang, Li-yan Cui","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: Tyrosine-methionine-aspartate-aspartate (YMDD) mutations were the main limitation of lamivudine (LAM) for treating chronic hepatitis B (CHB). The aim of this study was to evaluate whether LAM combined with IFN-α offer advantage over lamivudine monotherapy for the occurrence of YMDD mutations in CHB using a meta-analysis.Methodology: We searched electronic databases and calculated the odds ratios (OR) with their 95% confidence intervals (CI) and pooled the results.Results: Our meta-analysis indicated that the difference of YMDD mutation rates between the combination therapy of IFN-α2b, IFN-α2a and Peg-IFN-α2a respectively plus LAM and LAM monotherapy (95% CI, 3.25-9.70, 95% CI, 5.77-17.51, 95% CI, 6.79-26.13, respectively). The rate of YMDD mutations in LAM monotherapy was increased when compared with combination and sequential combination group (95% CI, 6.79-22.16, and 95% CI, 2.69-7.75, respectively). The YMDD mutation rate in combination therapy was lower than that of LAM monotherapy in HBeAg positive patients (95% CI, 4.98-13.23).Conclusions: Our present meta-analysis suggests that different types of IFN-a in combination with LAM can significantly reduce the rate of YMDD mutation compared to LAM monotherapy.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"133-9"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33130554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. 胰腺癌手术切除后的辅助S-1化疗。

Hepato-gastroenterology Pub Date : 2015-01-01

Hiroji Shinkawa, Takahiro Uenishi, Shigekazu Takemura, Chikaharu Sakata, Yorihisa Urata, Akinori Nozawa, Genya Hamano, Masahiko Kinoshita, Shoji Kubo

{"title":"Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.","authors":"Hiroji Shinkawa, Takahiro Uenishi, Shigekazu Takemura, Chikaharu Sakata, Yorihisa Urata, Akinori Nozawa, Genya Hamano, Masahiko Kinoshita, Shoji Kubo","doi":"","DOIUrl":"","url":null,"abstract":"Background/aims: The aim of this study was determine the effectiveness of adjuvant S-1 chemotherapy for patients with resected pancreatic cancer.Methodology: Patients with pancreatic carcinoma who underwent pancreatic resection without adjuvant S-1 chemotherapy (n = 11) or with adjuvant S-1 chemotherapy (n = 10) were included. S-1 was administered orally at a dose of 40 mg/m2 twice daily for 28 consecutive days followed by a 14-day pause. The cycle was repeated 4 times. Overall and disease-free survival curves were generated using the Kaplan-Meier method, and statistical differences between groups were analyzed using the log-rank test.Results: The disease-free survival and overall survival were longer among recipients of adjuvant S-1 chemotherapy than among those who received surgery alone (P < 0.05; 5-year disease-free survival rate, 30% versus 0%; 5-year overall survival rate, 65% vs 0%). Although dose reduction was needed in 2 patients because of grade 2 anorexia, only 1 patient with grade 2 hypoalbuminemia discontinued adjuvant chemotherapy because of long-term hospitalization.Conclusions: S-1 administered as a single agent showed promise as an adjuvant chemotherapy for resected pancreatic cancer.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"169-74"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33130561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0